Cytomegalovirus in Solid Organ Transplantation
Raymund R. Razonable,Atul Humar +1 more
Reads0
Chats0
TLDR
Primary infection manifests as an asymptomatic or self-limited febrile illness in immunocompetent individuals, after which CMV establishes life-long latency in various cells, which serve as reservoirs for reactivation and as carriers of infection to susceptible individuals.About:
This article is published in American Journal of Transplantation.The article was published on 2013-03-01 and is currently open access. It has received 444 citations till now. The article focuses on the topics: Congenital cytomegalovirus infection & Ganciclovir.read more
Citations
More filters
Journal ArticleDOI
The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation
Camille N. Kotton,Deepali Kumar,Angela M. Caliendo,Shirish Huprikar,Sunwen Chou,Lara Danziger-Isakov,Atul Humar +6 more
TL;DR: Highlights include advances in molecular and immunologic diagnostics, improved understanding of diagnostic thresholds, optimized methods of prevention, advances in the use of novel antiviral therapies and certain immunosuppressive agents, and more savvy approaches to treatment resistant/refractory disease.
Journal ArticleDOI
Infection in Organ Transplantation
TL;DR: Transplant infectious disease remains a key to the clinical and scientific investigation of organ transplantation and application of quantitative molecular microbial assays and advanced antimicrobial therapies have advanced care.
Journal ArticleDOI
Cytomegalovirus infections in solid organ transplantation: a review.
TL;DR: An overview of the contemporary epidemiology, clinical presentation, diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients is provided.
Journal ArticleDOI
Cytomegalovirus infection in transplant recipients
Luiz Sergio Azevedo,Lígia Camera Pierrotti,Edson Abdala,Silvia Figueiredo Costa,Tânia Mara Varejão Strabelli,Silvia Vidal Campos,Jessica Fernandes Ramos,Acram Zahredine Abdul Latif,Nadia Litvinov,Natalya Zaidan Maluf,Helio Hehl Caiaffa Filho,Cláudio Sérgio Pannuti,Marta Heloísa Lopes,Vera Aparecida dos Santos,Camila da Cruz Gouveia Linardi,Maria Aparecida Shikanai Yasuda,Heloisa Helena de Sousa Marques +16 more
TL;DR: Cytomegalovirus infection is a frequent complication after transplantation and can be prevented by prophylaxis or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease).
Journal ArticleDOI
Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation
TL;DR: This review article synthesizes the vast amount of information on CMV NAT and provides a timely review of the clinical utility of viral load testing in the management of CMV in solid organ transplant recipients.
References
More filters
Journal ArticleDOI
Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection.
TL;DR: Despite high seroprevalences in some populations, a substantial percentage of women of reproductive age are CMV seronegative and thus at risk of primary CMV infection during pregnancy, and future vaccine or educational campaigns to prevent primary infection in pregnant women may need to be tailored to suit the needs of different populations.
Journal ArticleDOI
Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
TL;DR: This study seeks to update the definitions of CMV on the basis of recent developments in diagnostic techniques, as well as to add to these definitions the concept of indirect effects caused by CMV.
Journal ArticleDOI
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
Carlos V. Paya,Atul Humar,Ed Dominguez,Kenneth Washburn,Emily A. Blumberg,Barbara D. Alexander,Richard B. Freeman,Nigel Heaton,Mark D. Pescovitz +8 more
TL;DR: Once‐daily oral valganciclovir was as clinically effective and well‐tolerated as oral ganciclovIR tid for CMV prevention in high‐risk SOT recipients and the safety profile was similar for both drugs.
Journal ArticleDOI
Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
David C. Lowance,Hans H. Neumayer,Christophe Legendre,Jean-Paul Squifflet,Josef Kovarik,Patrick J. Brennan,Douglas Norman,Rafael Mendez,Michael R. Keating,Gary L. Coggon,Adam Crisp,Ira C. Lee +11 more
TL;DR: Prophylactic treatment with valacyclovir is a safe and effective way to prevent CMV disease after renal transplantation and decreased the rates of CMV viremia and viruria, herpes simplex virus disease, and the use of inpatient medical resources.
Journal ArticleDOI
Cytomegalovirus Seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988–2004
TL;DR: The substantial disparities in CMV risk among seronegative women suggest that prevention strategies should include an emphasis on reaching racial or ethnic minorities and women of low socioeconomic status.